Tags

Type your tag names separated by a space and hit enter

Progestins' actions in the VTA to facilitate lordosis involve dopamine-like type 1 and 2 receptors.
Pharmacol Biochem Behav 2004; 78(3):405-18PB

Abstract

In the ventral tegmental area (VTA), 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP) facilitates lordosis. Whether this involves dopamine type 1 (D1) or dopamine type 2 (D2) receptors is of interest. Ovariectomized (ovx) rats with guide cannulae to the VTA were estradiol (E2) primed and pretested for lordosis. Rats were then infused with the D1 (Experiment 1) or D2 (Experiment 2) antagonists or agonists (0, 100, or 200 ng) to the VTA and were retested. After a second infusion of 3alpha,5alpha-THP (0, 100, or 200 ng) or vehicle, rats were tested 10, 60, and 120 min later. In Experiment 3, rats were administered a progestin receptor antagonist, RU38486, systemically or to the VTA 1 h prior to vehicle, SKF38393 and/or 3alpha,5alpha-THP infusions. 3alpha,5alpha-THP infusions increased lordosis over that seen with E2 priming. The D1 antagonist, SCH23390, attenuated 3alpha,5alpha-THP, but not E2-facilitated lordosis. The D1 agonist, SKF38393, augmented 3alpha,5alpha-THP, but not E2-facilitated lordosis. The D2 antagonist, sulpiride, had no significant effects on lordosis. The D2 agonist, quinpirole, prevented 3alpha,5alpha-THP-facilitated lordosis. RU38486 (subcutaneous) inhibited lordosis, whereas infusions to the VTA decreased lordosis produced by SKF38393 and 3alpha,5alpha-THP, but not 3alpha,5alpha-THP alone. Thus, 3alpha,5alpha-THP's actions in the VTA for lordosis may involve D1 and/or D2 receptors.

Authors+Show Affiliations

Department of Psychology, The University at Albany-SUNY, Albany, NY 12222, USA. cafrye@cnsunix.albany.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

15251249

Citation

Frye, Cheryl A., et al. "Progestins' Actions in the VTA to Facilitate Lordosis Involve Dopamine-like Type 1 and 2 Receptors." Pharmacology, Biochemistry, and Behavior, vol. 78, no. 3, 2004, pp. 405-18.
Frye CA, Walf AA, Sumida K. Progestins' actions in the VTA to facilitate lordosis involve dopamine-like type 1 and 2 receptors. Pharmacol Biochem Behav. 2004;78(3):405-18.
Frye, C. A., Walf, A. A., & Sumida, K. (2004). Progestins' actions in the VTA to facilitate lordosis involve dopamine-like type 1 and 2 receptors. Pharmacology, Biochemistry, and Behavior, 78(3), pp. 405-18.
Frye CA, Walf AA, Sumida K. Progestins' Actions in the VTA to Facilitate Lordosis Involve Dopamine-like Type 1 and 2 Receptors. Pharmacol Biochem Behav. 2004;78(3):405-18. PubMed PMID: 15251249.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Progestins' actions in the VTA to facilitate lordosis involve dopamine-like type 1 and 2 receptors. AU - Frye,Cheryl A, AU - Walf,Alicia A, AU - Sumida,Kanako, PY - 2004/02/10/received PY - 2004/03/29/revised PY - 2004/04/09/accepted PY - 2004/7/15/pubmed PY - 2005/1/27/medline PY - 2004/7/15/entrez SP - 405 EP - 18 JF - Pharmacology, biochemistry, and behavior JO - Pharmacol. Biochem. Behav. VL - 78 IS - 3 N2 - In the ventral tegmental area (VTA), 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP) facilitates lordosis. Whether this involves dopamine type 1 (D1) or dopamine type 2 (D2) receptors is of interest. Ovariectomized (ovx) rats with guide cannulae to the VTA were estradiol (E2) primed and pretested for lordosis. Rats were then infused with the D1 (Experiment 1) or D2 (Experiment 2) antagonists or agonists (0, 100, or 200 ng) to the VTA and were retested. After a second infusion of 3alpha,5alpha-THP (0, 100, or 200 ng) or vehicle, rats were tested 10, 60, and 120 min later. In Experiment 3, rats were administered a progestin receptor antagonist, RU38486, systemically or to the VTA 1 h prior to vehicle, SKF38393 and/or 3alpha,5alpha-THP infusions. 3alpha,5alpha-THP infusions increased lordosis over that seen with E2 priming. The D1 antagonist, SCH23390, attenuated 3alpha,5alpha-THP, but not E2-facilitated lordosis. The D1 agonist, SKF38393, augmented 3alpha,5alpha-THP, but not E2-facilitated lordosis. The D2 antagonist, sulpiride, had no significant effects on lordosis. The D2 agonist, quinpirole, prevented 3alpha,5alpha-THP-facilitated lordosis. RU38486 (subcutaneous) inhibited lordosis, whereas infusions to the VTA decreased lordosis produced by SKF38393 and 3alpha,5alpha-THP, but not 3alpha,5alpha-THP alone. Thus, 3alpha,5alpha-THP's actions in the VTA for lordosis may involve D1 and/or D2 receptors. SN - 0091-3057 UR - https://www.unboundmedicine.com/medline/citation/15251249/Progestins'_actions_in_the_VTA_to_facilitate_lordosis_involve_dopamine_like_type_1_and_2_receptors_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091305704001340 DB - PRIME DP - Unbound Medicine ER -